Pacific Biosciences stock analysis
Pacific Biosciences (P09) Stock Price & Analysis
P09 Stock Chart & Stats
- Day’s Range
- EUR 1.65 - EUR 1.74
- 52-Week Range
- EUR 0.93 - EUR 2.97
- Previous Close
- EUR 1.68
- Volume
- N/A
- Average Volume (3M)
- 1,690
- Market Cap
- EUR 518.01M
- Enterprise Value
- EUR 1.24B
- Total Cash (Recent Filing)
- EUR 199.42M
- Total Debt (Recent Filing)
- EUR 705.37M
- Price to Earnings (P/E)
- ―
- Beta
- 0.09
- Next Earnings
- Feb 18, 2027 (Est.)
- EPS Estimate
- -0.11
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Clinical Growth
Clinical adoption is becoming a meaningful growth engine, with consumables revenue rising more than 20% year-over-year and testing moving toward commercialization. Greater clinical use can deepen recurring reagent demand, diversify customers beyond research markets, and support more durable platform utilization.
Installed-Base Expansion
Expansion of the Revio installed base strengthens PacBio’s razor-and-blades model because each placement can generate recurring consumables and service revenue. New customers, multi-instrument orders, and larger fleet deployments also increase utilization opportunities and reinforce workflow adoption.
Cost Reduction Roadmap
The planned reduction in compensation-related and development spending provides a defined path to lower operating expenses and reduced cash burn. If executed, these savings could extend financial runway, improve operating leverage, and move the company closer to sustainable cash generation.
Bears Say
Stressed Balance Sheet
Negative equity and substantial debt materially constrain financial flexibility while the company remains loss-making. This capital structure can limit investment choices, increase refinancing exposure, and make execution of product launches and commercial expansion more dependent on external financing.
Persistent Cash Burn
PacBio is still funding operations primarily through external capital rather than internally generated cash. Continued high cash burn reduces the resources available for research, commercialization, and debt management, while increasing the importance of achieving the company’s future cost and breakeven targets.
Margin Pressure
The decline in gross margin shows that product growth is not yet translating into stable economic performance. Higher component costs and transition expenses can compress contribution from instruments and consumables, making future profitability dependent on execution, scale benefits, and cost normalization.
P09 FAQ
What was Pacific Biosciences’s price range in the past 12 months?
What is Pacific Biosciences’s market cap?
When is Pacific Biosciences’s upcoming earnings report date?
How were Pacific Biosciences’s earnings last quarter?
Is Pacific Biosciences overvalued?
Does Pacific Biosciences pay dividends?
What is Pacific Biosciences’s EPS estimate?
How many shares outstanding does Pacific Biosciences have?
What happened to Pacific Biosciences’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Pacific Biosciences?
What is the TipRanks Smart Score and how is it calculated?
Pacific Biosciences Stock Smart Score
Company Description
Pacific Biosciences
Pacific Biosciences of California, Inc. (PACB) specializes in pioneering and manufacturing advanced genetic sequencing platforms, empowering researchers and institutions to unravel intricate genetic challenges. At the heart of its offerings are the proprietary PacBio Sequencing Systems, designed for executing, monitoring, and interpreting biochemical sequencing reactions. Complementing these instruments are essential consumable products, such as their unique single molecule real-time (SMRT) cells. Furthermore, the company supplies a comprehensive suite of workflow-specific reagent kits. These include template preparation kits, which utilize molecular biology reagents (like ligase, buffers, and exonucleases) to convert DNA into SMRTbell double-stranded DNA libraries. Binding kits, featuring modified DNA polymerase, facilitate the crucial attachment of SMRTbell libraries to the polymerase in readiness for sequencing. Finally, specialized sequencing kits contain all necessary reagents, including phospholinked nucleotides, for real-time sequencing directly on their instruments. Pacific Biosciences caters to a broad global clientele, encompassing prominent research institutions, commercial diagnostic laboratories, large-scale genome centers, public health organizations, hospitals, clinical research institutes, contract research organizations (CROs), academic bodies, pharmaceutical firms, and agricultural enterprises. Product commercialization is managed through a direct sales force across North America and Europe, complemented by a robust network of distribution partners spanning Asia, the Middle East, Africa, and Latin America. A significant strategic alliance includes a development and commercialization agreement with Invitae Corporation. Originally incorporated in 2000 as Nanofluidics, Inc., the company adopted its current name, Pacific Biosciences of California, Inc., in 2005. Its corporate headquarters are situated in Menlo Park, California.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Mark Van Oene
- Employees
- 485
- Website
- www.pacb.com
- Address
- 1305 O’Brien Drive, Menlo Park, CA, 94025, US
Pacific Biosciences (P09) Earnings & Revenues
P09 Company Deck
P09 Earnings Call
Earnings Call SentimentPositive
The call was broadly positive, with improving SPRQ-Nx adoption, clinical growth above 20% year-over-year, stronger instrument placements, strategic clinical and AI partnerships, and continued progress toward operating expense reduction and a 2028 cash flow breakeven target. These positives were tempered by lower year-over-year consumables revenue, a decline in gross margin, constrained academic and government funding, a reduced cash balance, and ongoing regional and capital-spending challenges.
View all DE:P09 earnings summariesP09 Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 9 | 2 | 11 |
| Technical Analysis | 5 | 2 | 3 |
| Moving Averages | 4 | 0 | 8 |












